RESUMEN

BACKGROUND: Emergence of anti-HBe following seroconversion of HBe antigen indicates reduced hepatitis B virus (HBV) replication in the liver and low infectivity in the natural course of infection. However, some patients show continued replication or reactivation even in the presence of anti-HBe. OBJECTIVE: To clarify the cause of HBV replication, we investigated genotype differences and mutations in the core promoter and precore region in relation to virus titer. STUDY DESIGN: Using quantification of HBV DNA, nucleotide sequencing of the core promoter and precore region, and genotyping with the S gene by restriction fragment length polymorphism (RFLP), we analyzed sera of 26 anti-HBe positive carriers (28 serum samples). RESULTS: Various mutations were detected including C to T point mutation at nt 1653, A to T and G to A contiguous point mutations at nt 1762 and 1764 in the core promoter region, and G to A point mutation at nt 1896 in the precore region, but no common mutations were detected that were directly related to the virus titer from earlier reported mutations. In contrast, the mean titer of genotype B virus was 1.5 x 10(5) copies per ml and that of mutant HBV of genotype C having 8 base pairs (8-bp) deletion (nt 1768-1775) in the core promoter region was 7.9 x 10(4) copies per ml (mean titer). These titers showed commonly lower than that of genotype C virus without 8-bp deletion (median titer 5.0 x 10(6) copies per ml). Transition of genotype from C to B after viral reactivation and reduction of proportion of 8-bp deletion mutant at reactivation period was observed in a patient who demonstrated exacerbation of liver dysfunction due to immunosuppressive therapy and increased viral replication. CONCLUSIONS: These results confirm those of our earlier study describing low replication ability of 8-bp deletion mutant HBV in vitro, and also indicate that the presence of genotype B correlates with reduced titer of HBV.

Asunto(s)

Portador Sano/virología , Anticuerpos Antihepatitis/sangre , Virus de la Hepatitis B/genética , Hepatitis B/virología , Proteínas del Núcleo Viral/genética , Adulto , Anciano , Portador Sano/inmunología , Femenino , Genotipo , Antígenos e de la Hepatitis B/inmunología , Virus de la Hepatitis B/clasificación , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mutación , Mutación Puntual , Regiones Promotoras Genéticas , Replicación Viral

RESUMEN

We have demonstrated previously the presence of an 8-bp deletion mutant, spanning from nt. 1768 to nt. 1775 in the basic core promoter region of hepatitis B virus (HBV) in patients with anti-HBe positive asymptomatic phase before developing acute exacerbation after immunosuppressive treatment. The transcription and progeny virus production activities of the mutant were examined by transfection of the recombinant plasmid [pUC Del(2)] containing the head-to-tail dimer DNA of the mutant into HepG2 cells. The amounts of hepatitis B surface antigen (HBsAg) and HBe antigens secreted into the culture medium were markedly reduced. Southern blotting of DNAs extracted from the culture medium also showed reduced mutant activity to produce progeny virus. Northern blotting and RNase protection assay of RNAs extracted from transfected cells demonstrated that the transcription of both precore mRNA and pregenome RNA was reduced significantly compared to that of wild-type HBV. The promoter activity examined by transfection of the CAT plasmid containing deletion mutant DNA was much lower than that of wild type. Co-transfection experiments, however, of the CAT plasmid containing wild-type DNA with pUC Del(2) reduced CAT activity induced by wild-type, suggesting that truncated X protein produced by the mutant does not possess a sufficient transactivating activity. Gel shift assay using HepG2 nuclear extract and a probe containing four TA-rich regions in CP and various competitors suggested that the lack of the third TA-rich region was responsible for the transcription reduction of precore mRNA and pregenome RNA. The possible mechanisms are discussed.

Asunto(s)

Virus de la Hepatitis B/genética , Regiones Promotoras Genéticas , Transcripción Genética , Secuencia de Bases , Northern Blotting , Southern Blotting , Antígenos de la Hepatitis B/biosíntesis , Virus de la Hepatitis B/metabolismo , Humanos , Proteínas Nucleares/metabolismo , Unión Proteica , Eliminación de Secuencia , Células Tumorales Cultivadas

RESUMEN

We examined the efficacy of therapeutic oral vaccination using Helicobacter pylori-whole cell sonicate and cholera toxin (CT) in mice persistently infected with H. pylori. Efficacy was determined by bacterial culture and microscopic examination of gastric tissues for the persistence of bacteria at 6 weeks after the last vaccination. Vaccination of H. pylori-whole cell sonicate combined with CT eradicated bacteria in 10/16 mice (62.5%). Interestingly, oral vaccination with CT alone also eliminated the bacteria in 8/17 mice (47.1%). However, a therapeutic intraperitoneally administered vaccine failed to eradicate H. pylori from the stomach (1/17 mice, 5.9%). Identification of the type of immunity involved in the eradication process showed that oral vaccination enhanced the antigen-specific IgA in the feces and saliva. The efficacy of eradication of H. pylori correlated well with increases in IgA secretion in mucosal tissue and a higher labeling index of IgA-positive lumina of pyloric glands. Moreover, the expression of IL-4 mRNA in the stomach of mice with eradicated bacteria was higher than in the uneradicated group. Our results suggest that the efficacy of vaccination depends on the mucosal IgA response in the gastrointestinal tract against H. pylori via Th2 cell activation and that therapeutic oral vaccination induces a mucosal immune response sufficient to eradicate long-term infection with H. pylori.

Asunto(s)

Vacunas Bacterianas/inmunología , Mucosa Gástrica/inmunología , Infecciones por Helicobacter/terapia , Helicobacter pylori/inmunología , Administración Oral , Animales , Anticuerpos Antibacterianos/inmunología , Vacunas Bacterianas/uso terapéutico , Enfermedad Crónica , Femenino , Mucosa Gástrica/patología , Expresión Génica , Infecciones por Helicobacter/microbiología , Infecciones por Helicobacter/patología , Humanos , Inmunidad Mucosa/inmunología , Inmunoglobulina A Secretora/análisis , Interferón gamma/genética , Interleucina-4/genética , Ratones , Ratones Endogámicos C57BL , ARN Mensajero/genética , ARN Mensajero/metabolismo , Factores de Tiempo , Vacunación

RESUMEN

C57BL/6 mice were orally immunized with five weekly doses of 2 mg, 200 microgram, or 2 microgram of Helicobacter pylori (Sydney strain) whole-cell sonicate combined with cholera toxin. One week after the last vaccination, mice were challenged with 5 x 10(7) CFU of live H. pylori three times at 2-day intervals. At 6 or 18 weeks after the challenge, mice were sacrificed and bacterial cultures and histological studies of the stomach were performed. Vaccination with 2 mg/session or 200 microgram/session inhibited H. pylori colonization by 90 and 100%, respectively. These mice were considered protected. Lower levels of H. pylori-specific immunoglobulin A (IgA) were detected in fecal and saliva samples before challenge. However, a significant increase in IgA secretion in mucosal tissue and a higher labeling index for IgA-positive lumina of pyloric glands were noted in these mice in response to challenge and in a vaccine dose-dependent manner. In protected mice, however, severe gastritis characterized by marked infiltration of inflammation mononuclear cells was noted at 6 weeks after challenge, compared with the gastritis seen in unprotected mice or nonvaccinated, ordinarily infected mice. Marked expression of gamma interferon mRNA was detected in the stomach of all protected mice, and 50% of these mice expressed interleukin 4 (IL-4) or IL-5 mRNA. Our findings suggest that local secretory IgA antibody and severe postimmunization gastritis correlate well with protection of mice against H. pylori infection.

Asunto(s)

Vacunas Bacterianas/efectos adversos , Gastritis/etiología , Infecciones por Helicobacter/inmunología , Infecciones por Helicobacter/prevención & control , Helicobacter pylori/inmunología , Inmunización/efectos adversos , Inmunoglobulina A Secretora/metabolismo , Administración Oral , Animales , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/metabolismo , Vacunas Bacterianas/administración & dosificación , Recuento de Colonia Microbiana , Citocinas/genética , Modelos Animales de Enfermedad , Relación Dosis-Respuesta Inmunológica , Heces/microbiología , Femenino , Gastritis/inmunología , Gastritis/patología , Expresión Génica , Helicobacter pylori/aislamiento & purificación , Inmunoglobulina A Secretora/sangre , Inmunoglobulina G/sangre , Inmunoglobulina G/clasificación , Interferón gamma/genética , Ratones , Ratones Endogámicos C57BL , ARN Mensajero/genética , ARN Mensajero/metabolismo , Saliva/inmunología

RESUMEN

Eradication of Helicobacter pylori infection cures gastritis and prevents recurrence of peptic ulcers. Endoscopy is usually used to evaluate the effectiveness of eradication therapy. We designed a new noninvasive assay system for the early evaluation of eradication of H. pylori infection in which a crude H. pylori outer membrane protein preparation (HPOmp) is used as an antigen, and we determined the sensitivity and specificity of the serological assay system. Immunoblot analysis showed that anti-HPOmp antibodies reacted to a protein with a molecular mass of approximately 29 kDa. In those patients who responded to therapy, the anti-HPOmp immunoglobulin G (IgG) titers measured by enzyme-linked immunosorbent assay (ELISA) at 1 month after the end of therapy were significantly lower than those before treatment (34.8% reduction; P < 0.001), and the posttreatment reduction in the antibody titer was significantly greater than that of the titer measured with a commercially available anti-H. pylori IgG ELISA (34.8% versus 16.1%; P < 0.001). When a 25% reduction of anti-HPOmp IgG titer at 1 month after the end of treatment was taken as the cutoff value for H. pylori eradication, the sensitivity and specificity of our new assay were 75% (51 of 68 treatment responders) and 96% (22 of 23 nonresponders), respectively. Our results indicate that the novel serological test with HPOmp might be a clinically useful tool for assessment of eradication of H. pylori.

Asunto(s)

Anticuerpos Antibacterianos/sangre , Proteínas de la Membrana Bacteriana Externa/inmunología , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/inmunología , Adolescente , Adulto , Anciano , Antígenos Bacterianos/inmunología , Ensayo de Inmunoadsorción Enzimática , Estudios de Evaluación como Asunto , Femenino , Infecciones por Helicobacter/inmunología , Infecciones por Helicobacter/microbiología , Humanos , Immunoblotting , Recién Nacido , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad , Resultado del Tratamiento

RESUMEN

The nucleotide sequences of the core upstream and precore regions (371 nucleotide length, nt. 1604-1974) of hepatitis B virus (HBV) were analysed sequentially in three subjects who were positive serologically for anti-HBe and had acute clinical exacerbation after immunosuppressive treatment. These patients were asymptomatic HBV carriers before therapy. The results revealed that the mutant with an 8-bp deletion (nt. 1768-1775) located in the basic core promoter region was dominant in the asymptomatic HBV carrier phase in two of three subjects. After exacerbation, however, such mutant clones possessing 8-bp deletion disappeared or decreased in number and were replaced by the clones possessing a precore stop codon mutation G to A (nt. 1896) or by the clones possessing additional contiguous point mutations A to T (nt. 1762) and G to A (nt. 1764) and a new point mutation C to T (nt. 1653). Possible relationships between acute exacerbation of liver function accompanied by mutation and the transition of the dominant clones were discussed.

Asunto(s)

Portador Sano , Genoma Viral , Anticuerpos contra la Hepatitis B/sangre , Antígenos e de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Hepatitis B/virología , Mutación , Enfermedad Aguda , Secuencia de Bases , Neoplasias Encefálicas/complicaciones , ADN Viral , Dermatomiositis/complicaciones , Femenino , Glioblastoma/complicaciones , Hepatitis B/complicaciones , Hepatitis B/inmunología , Hepatitis B/fisiopatología , Anticuerpos contra la Hepatitis B/inmunología , Antígenos e de la Hepatitis B/inmunología , Virus de la Hepatitis B/inmunología , Enfermedad de Hodgkin/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Precursores de Proteínas/genética , Análisis de Secuencia de ADN , Homología de Secuencia de Ácido Nucleico

RESUMEN

Genotyping of hepatitis C virus (HCV) of liver disease patients in the Dominican Republic was performed. Eighty-four samples positive for HCV antibody, which were confirmed by ELISA, particle agglutination, and recombinant immunoblot assay III tests, were subjected to HCV genotyping by polymerase chain reaction using type-specific primers located in the nonstructural protein 5 region. Of the 84 samples tested, 50 (59%) were found to have genotype 1a/I and this genotype was the most frequent type detected in the present study. The numbers of isolates of genotypes 1b/II, 2a/III, 2b/IV, and 3a/V were three (3.6%) six (7.1%), two (2.4%), and two 2.4%), respectively. The number of samples having mixed genotype populations was 16 (19%). The possible causes of the high prevalence of genotype 1a/I in the Dominican Republic compared with other countries and of the high detection ratio of samples having mixed genotypes are discussed.

Asunto(s)

ADN Complementario/análisis , Anticuerpos contra la Hepatitis C/análisis , Hepatitis C/genética , ARN Viral/genética , Proteínas no Estructurales Virales/genética , Pruebas de Aglutinación , República Dominicana/epidemiología , Ensayo de Inmunoadsorción Enzimática , Femenino , Genotipo , Hepacivirus/genética , Hepacivirus/inmunología , Hepatitis C/epidemiología , Hepatitis C/inmunología , Humanos , Immunoblotting , Hepatopatías/diagnóstico , Hepatopatías/epidemiología , Hepatopatías/virología , Masculino , Reacción en Cadena de la Polimerasa , Prevalencia , ARN Viral/análisis , ARN Viral/aislamiento & purificación , Proteínas Recombinantes/inmunología , Sensibilidad y Especificidad

RESUMEN

Rabies virus M protein was expressed in Escherichia coli in the form of a fusion protein with maltose binding protein (MBP) and purified by amylose affinity column chromatography after extraction. In order to investigate the possible regulatory role of M protein in viral transcription, an assay system for rabies virion-associated transcriptase activity was established by using the ribonucleoprotein (RNP) cores prepared from purified virions. Analysis of the products of the transcription assay system showed that the products are sensitive to RNase and are positive-strand RNA. Addition of the fusion protein to the system after cleavage with a proteinase Factor Xa (FXa), which cleaves the fusion protein into the M protein and MBP, resulted in an efficient and dose-dependent inhibition of the transcription. Furthermore, addition to the system of anti-M protein monoclonal antibody significantly restored the transcription. Control experiments with the same transcription assaying system using rabies virus nucleoprotein expressed as a fusion protein with MBP and cleaved with FXa did not result in an inhibition of the transcription. These results suggest that the M protein of rabies virus has the property to down-regulate virion-associated transcription.

Asunto(s)

Transportadoras de Casetes de Unión a ATP , ARN Polimerasas Dirigidas por ADN/metabolismo , Proteínas de Escherichia coli , Regulación Viral de la Expresión Génica , Proteínas de Transporte de Monosacáridos , Virus de la Rabia/fisiología , Proteínas de la Matriz Viral/fisiología , Animales , Anticuerpos Monoclonales/inmunología , Secuencia de Bases , Proteínas Portadoras/genética , Línea Celular , Cricetinae , Cartilla de ADN , Regulación hacia Abajo , Escherichia coli , Proteínas de Unión a Maltosa , Datos de Secuencia Molecular , Virus de la Rabia/enzimología , Virus de la Rabia/genética , Proteínas Recombinantes de Fusión/genética , Transcripción Genética , Proteínas de la Matriz Viral/genética , Virión/enzimología

RESUMEN

Serotonin 5-HT2C receptor-mediated intracellular Ca2+ mobilization was investigated in Chinese hamster ovary (CHO) cells transfected with 5-HT2C receptors. Fura-2 acetoxymethyl ester was used to investigate the regulation of 5-HT2C receptor function. CHO cells, transfected with a cDNA clone for the 5-HT2C receptor, expressed 287 fmol/mg of the receptor protein as determined by mianserin-sensitive [3H]mesulergine binding (KD = 0.49 nM). The addition of 5-HT mobilized intracellular Ca2+ in a dose-dependent fashion, ranging from a basal level of 99 +/- 1.8 up to 379 +/- 18 nM, with an EC50 value for 5-HT of 0.029 microM. Exposure to 5-HT, 1-(3-chlorophenyl)piperazine dihydrochloride (a 5-HT2C agonist), and 1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane (a 5-HT2C and 5-HT2A agonist) resulted in increased intracellular Ca2+ levels. Mianserin, mesulergine, ritanserin, and ketanserin each blocked 5-HT-mediated intracellular Ca2+ mobilization more effectively than spiperone. The receptor was rapidly desensitized by preexposure to 5-HT in a time- and concentration-dependent manner. Mezerein and phorbol 12-myristate 13-acetate, protein kinase C activators, weakly inhibited the intracellular Ca2+ mobilization induced by 10 microM 5-HT. Furthermore, the protein kinase C inhibitor H-7 partially prevented the protein kinase C activator-induced inhibition of the 5-HT-mediated increase in intracellular Ca2+ concentration. The desensitization induced by pretreatment with 5-HT was blocked by W-7, added in conjunction with 5-HT, and partially inhibited by W-5, a nonselective inhibitor of protein kinases and weak analogue of W-7.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Células CHO/fisiología , Calcio/metabolismo , Membranas Intracelulares/metabolismo , Receptores de Serotonina/genética , Receptores de Serotonina/metabolismo , Transfección , Animales , Transporte Biológico , Cricetinae , Humanos , Proteína Quinasa C/fisiología , Receptores de Serotonina/clasificación , Antagonistas de la Serotonina/farmacología , Agonistas de Receptores de Serotonina/farmacología , Sulfonamidas/farmacología

RESUMEN

We evaluated the effect of transferrin on the regulation of granulosa cell function in humans by evaluating the production of progesterone (P) in the preovulatory phase in vivo, and in cultured porcine granulosa cells in vitro. Twenty-five women treated for in vitro fertilization and embryo transfer had their serum levels of 17 beta-estradiol (E2) and P determined on the day of administration of human chorionic gonadotropin. Transferrin concentrations were also determined in ovarian follicular fluid. In an in vitro study, porcine granulosa cells were cultured in the presence of follicle-stimulating hormone (FSH) and transferrin. Serum levels of P showed a significant negative correlation with those of transferrin (r = -0.53, p < 0.01), whereas serum levels of E2 did not (r = 0.14). When the subjects were divided into two groups by serum P concentration (low P < 1 ng/ml, high P > or = 1 ng/ml) serum concentrations of transferrin were significantly increased in the group with the low versus the high level of p (p < 0.01). Production of P by porcine granulosa cells was suppressed by transferrin in the presence of various concentrations of FSH. Increasing the dose of transferrin significantly suppressed the production of P by those cells in a dose-dependent fashion. The production of P during the preovulatory phase may be suppressed by transferrin in the granulosa cells.

Asunto(s)

Células de la Granulosa/efectos de los fármacos , Progesterona/metabolismo , Transferrina/farmacología , Adulto , Animales , Femenino , Células de la Granulosa/metabolismo , Humanos , Progesterona/sangre , Porcinos

RESUMEN

The regulatory regions for transcription and replication of several hepatitis B virus (HBV) genomes from 19 patients having various forms of HBV infection were sequenced. Predominant mutations were found to occur naturally in nucleotide positions 1762 (A to T) and 1764 (G to A) in chronic hepatitis patients and in asymptomatic carriers after seroconversion, but were not observed in HBeAg-positive healthy carriers. Since these positions were located in the basic core promoter and the overlapping enhancer II regions situated within the core upstream region, transcriptional activity was examined by chloramphenicol acetyltransferase assay to determine if there was a possible difference between the mutant and wild-type HBV. However, no significant difference was detected upon comparison of the promoter and enhancer activities between mutant and wild-type HBV.

Asunto(s)

Elementos de Facilitación Genéticos , Virus de la Hepatitis B/genética , Regiones Promotoras Genéticas , Transcripción Genética , Secuencia de Bases , Cloranfenicol O-Acetiltransferasa/genética , ADN Viral/análisis , Regulación Viral de la Expresión Génica , Humanos , Datos de Secuencia Molecular , Mutación , Sistemas de Lectura Abierta , Reacción en Cadena de la Polimerasa

RESUMEN

Transcription of the core (C) gene of hepatitis B virus DNA (HBV-DNA) was studied by an in vitro transcription system using nuclear extracts of human liver cell (HepG2) and non-liver cell (HeLa) origins. RNA polymerase II-dependent run-off transcription of 3.5-kb (C) mRNA was observed in both nuclear extracts; but the efficiency was much higher in the HepG2 nuclear extract. Analysis of run-off transcripts using upstream deletion mutants of HBV-DNA demonstrated that there are two transcription start sites located at approximately nucleotide numbers (nt) 1,797 +/- 5 and 1,815 +/- 5. This analysis also suggested that the minimum core promoter sequence and a cis-acting and liver-specific element for C mRNA transcription are located in the downstream region from -80 and -110 (HincII site) of transcription start sites, respectively. DNA-binding protein assays using synthetic double-stranded oligonucleotide probes corresponding to three regions in the upstream region (nt from 1,401 to 1,760) of transcription start sites revealed that there are some liver cell-specific and non-specific DNA-binding proteins in both nuclear extracts. The amount of those proteins was generally higher in the HepG2 nuclear extract. However, no obvious correlation was observed in the present study between the presence of DNA-binding proteins and transcription activity of nuclear extracts in our system. The possible causes of this discrepancy are discussed.

Asunto(s)

ADN Viral/metabolismo , Virus de la Hepatitis B/genética , Secuencias Reguladoras de Ácidos Nucleicos/genética , Transcripción Genética , Proteínas del Núcleo Viral/genética , Secuencia de Bases , Extractos Celulares/química , Núcleo Celular/química , ADN Viral/genética , Proteínas de Unión al ADN/análisis , Proteínas de Unión al ADN/metabolismo , Genes Virales/genética , Células HeLa , Humanos , Hígado/citología , Datos de Secuencia Molecular , Polidesoxirribonucleótidos/síntesis química , Polidesoxirribonucleótidos/metabolismo , ARN Polimerasa II/metabolismo , ARN Mensajero/biosíntesis , ARN Viral/biosíntesis , Eliminación de Secuencia/fisiología , Células Tumorales Cultivadas

RESUMEN

Mice vaccinated intraperitoneally (i.p.) with 10(7) p.f.u. of a vaccinia virus recombinant expressing either the glycoprotein (rVac-G) or nucleoprotein (rVac-N) of rabies virus 3 weeks before challenge were protected against peripheral lethal infection. Similarly, by post-exposure vaccination in which mice were first infected with rabies virus and subsequently vaccinated i.p. with the recombinant, rVac-G conferred protection when given immediately following infection and up to 24 h after infection. Prior treatment of those mice with anti-CD8 monoclonal antibodies (MAb) did not significantly affect the outcome of the infection. In contrast, rVac-N failed to confer protection even with higher doses (10(8) p.f.u.) of the virus or even when administered by the intradermal route. Anti-nucleoprotein antibody production by these mice was not suppressed by prior rabies virus infection and the levels and the time of antibody production were similar to those of anti-glycoprotein antibody production in mice vaccinated with rVac-G after rabies virus infection. The cytotoxic T lymphocyte response was also not down-regulated by rabies virus in the mice that were given rVac-N. Possible mechanism(s) for the ineffectiveness of rVac-N by post-exposure vaccination in contrast to pre-exposure vaccination was discussed.

Asunto(s)

Antígenos Virales , Cápside/inmunología , Glicoproteínas/inmunología , Vacunas Antirrábicas/inmunología , Virus de la Rabia/inmunología , Rabia/prevención & control , Proteínas del Núcleo Viral/inmunología , Proteínas del Envoltorio Viral/inmunología , Animales , Anticuerpos Antivirales/biosíntesis , Formación de Anticuerpos , Antígenos CD8/inmunología , Citotoxicidad Inmunológica , Inmunidad Celular , Ratones , Ratones Endogámicos A , Rabia/inmunología , Proteínas Recombinantes/inmunología , Subgrupos de Linfocitos T/inmunología , Factores de Tiempo , Vacunas Sintéticas/inmunología , Virus Vaccinia

RESUMEN

By using a phage vector (lambda ZAP II) and the mRNA extracted from IMR-32 cells infected with the RC.HL strain of rabies virus, we constructed a cDNA library from which four nucleoprotein (N)-specific cDNA clones were obtained by Southern blot hybridization. These clones contained a cDNA insert of about 1.4 kb, in which the longest open reading frame was the same length as that reported for the N cDNA of three fixed strains, CVS, PV, and SAD B19. When the nucleotide and deduced amino acid sequences were compared between the RC.HL and the three strains, homology was within the range of 91.5-91.8% and 95.1-96.0%, respectively. Of 183 nucleotides of the RC.HL N-cDNA that were not identical to that of the corresponding site of at least one of the three strains, 41 were shared with the CVS strain, whereas only three were shared with either of the other two strains. In the amino acid sequence, we found 29 residues that were not shared in common with all of the four strains, 11 of which were the substitutions with radically different amino acids that might cause conformational changes of the protein, and, in addition, five of which were located in the region close to the C terminus. The number of such amino acid substitutions between the RC,HL and CVS strains was smaller than that of the other three strains. These results are not inconsistent with the presumption that the RC.HL and CVS strains originated from the same laboratory strain of the Pasteur viruses.

Asunto(s)

Cápside/genética , Genes Virales/genética , Vacunas Antirrábicas/genética , Virus de la Rabia/genética , Proteínas del Núcleo Viral/genética , Proteínas Estructurales Virales/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Clonación Molecular , ADN Complementario/análisis , Japón , Datos de Secuencia Molecular , Alineación de Secuencia , Análisis de Secuencia de ADN , Homología de Secuencia de Aminoácido

RESUMEN

Although the RC-HL strain of rabies virus is avirulent in adult mice, the amino acid at position 333 of its G protein is arginine, which is thought to be necessary for virulence in adult mice upon intracerebral inoculation of the virus. This result suggests that besides arginine at position 333, some other positions of G protein might also be involved in determining the virulence of rabies virus.

Asunto(s)

Antígenos Virales , Glicoproteínas/genética , Mutación , Vacunas Antirrábicas/biosíntesis , Virus de la Rabia/genética , Rabia/veterinaria , Proteínas del Envoltorio Viral/genética , Secuencia de Aminoácidos , Secuencia de Bases , Japón , Datos de Secuencia Molecular , Sistemas de Lectura Abierta/genética , Fenotipo , Reacción en Cadena de la Polimerasa , Rabia/prevención & control , Virus de la Rabia/clasificación , Virus de la Rabia/patogenicidad , Vacunas Atenuadas , Virulencia

RESUMEN

Target cells of cytotoxic T lymphocytes (CTL) directed to the individual structural proteins (except for the large polymerase (L) protein) of rabies virus were established by expressing only the respective protein in murine neuroblastoma (NA) and murine macrophage (J774-1) cell lines. Mice infected with the ERA strain of rabies virus developed CTL responses to all of these rabies virus proteins. The cytotoxic activity was abrogated by pretreatment of the effector cells with anti-CD8 monoclonal antibody (MAb) and complement but not with anti-CD4 MAb. Cell lysis by CTL was blocked in the presence of anti-major histocompatibility complex (MHC) class 1 antibodies in J774-1 cell lines. Rabies virus-infected cells express these proteins at the surface, which can be recognized and lysed by the respective CTL. Mice immunized with beta-propiolactone-inactivated virus induced a CTL response against glycoprotein but not against internal viral components. This assay system might be useful for further analysis of the possible contribution of these proteins in the cell-mediated immune protection against rabies.

Asunto(s)

Virus de la Rabia/inmunología , Linfocitos T Citotóxicos/inmunología , Proteínas Estructurales Virales/inmunología , Animales , Anticuerpos Antivirales/inmunología , Línea Celular , Pruebas Inmunológicas de Citotoxicidad , Citotoxicidad Inmunológica/inmunología , Regulación Viral de la Expresión Génica , Macrófagos/virología , Masculino , Ratones , Ratones Endogámicos A , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Neuroblastoma/virología , Rabia/inmunología , Rabia/microbiología , Virus de la Rabia/genética , Virus de la Rabia/crecimiento & desarrollo , Células Tumorales Cultivadas , Proteínas Estructurales Virales/análisis

RESUMEN

A once-daily dosage regimen has been recently recommended in the use of aminoglycoside antibiotics since they induce a postantibiotic effect. In choosing this regimen, one must determine the most appropriate time of day for administration of the drug. We investigated the effects of the timing of amikacin (AMK) administration on the kinetics, the efficacy against intraperitoneal infection with Pseudomonas aeruginosa, and the toxicity of AMK in mice with and without immunosuppression. We found circadian variations in the kinetics, efficacy, and toxicity of the drug in mice. Male and female ICR mice, which were housed under a light-dark (12:12 h) cycle with free food and water intake, were injected subcutaneously with AMK sulfate 50 mg/kg body wt. There was a circadian variation in AMK clearance for both sexes with the maximum value in the dark phase and the minimum in the light phase after a single administration. When AMK 500 mg/kg/day was repeatedly administered once daily for 30 days, higher toxicity was demonstrated in mice injected with the drug at the time of day with lower AMK clearance, although no difference was demonstrated in the toxicity between the two time points with different AMK clearance when AMK 1,500 mg/kg was administered in a single dose. The ED50 of AMK to cure the infected mice in the midlight phase (13:00 h) with lower clearance was significantly lower than that in the middark phase (01:00 h) with higher clearance. In contrast, the ED50 in the early light phase (09:00 h) was significantly lower than that in the early dark phase (21:00 h), although AMK clearance was no different between these two different time points. In mice premedicated with cyclophosphamide to suppress immune functions, the difference in the ED50 of AMK was still demonstrated between 13:00 and 01:00 h, but not between 09:00 and 21:00 h. The present study shows not only that there were circadian variations in both AMK clearance and toxicity after repeated administration, but also that there was a circadian variation in the efficacy of AMK in mice infected with P. aeruginosa. These results suggest that the timing of drug administration should be considered in pharmacotherapy with AMK and that the most appropriate time of administration in mice and nocturnal animals may be in the midlight (resting) phase. They also suggest that the ED50 of AMK against P. aeruginosa infection may be influenced not only by the circadian variation in pharmacokinetics but also by the variations in immune systems suppressed by cyclophosphamide.

Asunto(s)

Amicacina/farmacocinética , Ritmo Circadiano , Infecciones por Pseudomonas/metabolismo , Amicacina/uso terapéutico , Amicacina/toxicidad , Animales , Ciclofosfamida/inmunología , Esquema de Medicación , Femenino , Terapia de Inmunosupresión , Masculino , Ratones , Ratones Endogámicos ICR , Infecciones por Pseudomonas/tratamiento farmacológico , Infecciones por Pseudomonas/fisiopatología

Asunto(s)

Vacunas Antirrábicas , Rabia/epidemiología , Animales , Países en Desarrollo , Perros , Humanos , Rabia/prevención & control , Vacunas Antirrábicas/economía

RESUMEN

In order to study the relationships among the clinical features of hepatitis C patients, the presence of hepatitis C virus (HCV) RNA in their blood, and their serum antibody titers against the core protein of virus and to study the antibody levels in asymptomatic HCV carriers, a recombinant vaccinia virus containing a core protein gene was constructed. The recombinant virus expressed a protein with a molecular mass of 22 kDa in RK-13 cells as determined by Western blot (immunoblot) analysis. By using the cell lysate of virus-infected cells and serially diluted serum samples, core antibody titers in the groups of patients in the chronic hepatitis phase and in the convalescent phase as well as in asymptomatic carriers were determined by enhanced chemiluminescence Western blot analysis. Almost all patients in the chronic phase were shown to have high antibody titers of more than 1:500,000 and with no exception had of HCV RNA in their sera. On the other hand, patients who had recovered naturally and were in the convalescent phase were shown to have significantly lower antibody titers, and the antibody was not detected in the lowest serum dilution of 1:500 in 43% of these patients (three of seven total patients). Antibody levels of patients who showed a good response to interferon treatment decreased to intermediate levels between those of patients in the chronic phase and those of patients in convalescent phase. The antibody titers in asymptomatic carriers varied considerably from 1:500,000 to 1:500, and 41% (11 of 27 total individuals) of these carriers showed a high titer equivalent to that of those in the chronic phase. Core antibody was detected consistently in the individuals in whom HCV RNA was detected. This system for core antibody might be useful for identifying the stage of an apparent HCV infection.

Asunto(s)

Hepacivirus/inmunología , Anticuerpos Antihepatitis/sangre , Hepatitis C/inmunología , Secuencia de Bases , Western Blotting , Portador Sano/inmunología , Portador Sano/microbiología , ADN Viral/genética , Hepacivirus/genética , Hepatitis C/microbiología , Hepatitis C/terapia , Anticuerpos contra la Hepatitis C , Humanos , Datos de Secuencia Molecular , ARN Viral/sangre , ARN Viral/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Virus Vaccinia/genética , Proteínas del Núcleo Viral/genética , Proteínas del Núcleo Viral/inmunología

RESUMEN

Nucleotide sequences and the deduced amino acid sequences of the gene encoding the matrix (M) protein of the Nishigahara and the CVS strains of rabies virus have been determined. The M gene is 609 nucleotides long and is capable of coding for a peptide composed of 202 amino acids. Sequence comparison of these M genes with those of other stains [Pasteur (PV), ERA, Avol] revealed that there is 89.7-91.5% homology at the nucleotide level, and 90.1-92.1% homology at amino acid level, between almost all combinations of these strains. However, in the combinations of the PV and ERA strains, and the virulent CVS and the avirulent CVS-derived Avol strains, much higher homology was observed both at the nucleotide and amino acid levels. The predicted secondary structure and hydropathy profiles also exhibited similar features. Recombinant vaccinia virus containing the M gene was constructed. Sodium dodecyl sulfate (NaDodSO4)-polyacrylamide gel electrophoresis of the precipitates obtained by immune reaction of the recombinant virus-infected cell lysate with a monoclonal antibody against the M protein revealed that electrophoretic mobility of the expressed protein is indistinguishable from that of the authentic M protein from rabies virions.

Asunto(s)

Genes Virales , Virus de la Rabia/genética , Virus Vaccinia/genética , Proteínas de la Matriz Viral/genética , Secuencia de Aminoácidos , Secuencia de Bases , ADN Viral/genética , Expresión Génica , Datos de Secuencia Molecular , Recombinación Genética , Análisis de Secuencia de ADN , Especificidad de la Especie